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Human kallikrein 14 (KLK14) is a steroid hormone-regulated member of the tissue kallikrein family of serine proteases, for which a
prognostic and diagnostic value in breast cancer has been suggested. To further characterise the value of KLK14 as a breast tumour
marker, we have carefully analysed KLK14 expression in normal breast tissue and breast cancer both on the RNA level by real-time
RT-PCR (n¼39), and on the protein level (n¼127) using a KLK14-specific antibody for immunohistochemistry. We correlated
KLK14 protein expression data with available clinico-pathological parameters (mean follow-up time was 55 months) including patient
prognosis. KLK14 RNA expression as quantified by real-time RT-PCR was significantly more abundant in breast tumours compared to
normal breast tissue (P¼0.027), an issue that had not been clarified recently. Concordantly with the RNA data, cytoplasmic KLK14
protein expression was significantly higher in invasive breast carcinomas compared to normal breast tissues (P¼0.003). Furthermore,
KLK14 protein expression was associated with higher tumour grade (P¼0.041) and positive nodal status (P¼0.045) but was not
significantly associated with shortened disease-free or overall patient survival time in univariate analyses. We conclude that KLK14 is
clearly overexpressed in breast cancer in comparison to normal breast tissues and is positively associated with conventional
parameters of tumour aggressiveness, but due to a missing association with survival times, the use of KLK14 immunohistochemistry as
a prognostic marker in breast cancer is questionable.
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Human tissue kallikreins comprise a family of 15 secreted serine
proteases, encoded by a multigene cluster (KLK genes) on
chromosome 19q13.4 (Diamandis et al, 2000; Borgono et al,
2004; Clements et al, 2004). This family includes the most
important serum tumour marker in clinical medicine for the early
detection, risk stratification, clinical staging, and monitoring of
prostate cancer, kallikrein 3 (KLK3), which is better known as
prostate-specific antigen (PSA) (Diamandis, 1998). In recent years,
many kallikreins in addition to KLK3/PSA, such as KLK2, KLK4,
KLK5, KLK6, KLK7, KLK8, KLK9, KLK10, KLK11, KLK13, and
KLK15 were found to be candidate biomarkers for several
endocrine-related malignancies, including breast, ovarian and
prostate cancers, demonstrating the immense clinical applicability
of this family (Diamandis and Yousef, 2002; Borgono and
Diamandis, 2004). With respect to breast cancer in particular,
several kallikrein family members, namely KLK3 (Yu et al, 1996),
KLK5 (Yousef et al, 2003c), KLK6 (Anisowicz et al, 1996), KLK10
(Liu et al, 1996; Dhar et al, 2001), KLK12 (Yousef et al, 2000b),
KLK13 (Yousef et al, 2000a), and KLK14 (Borgono et al, 2003) were
shown to be differentially expressed at the mRNA or protein levels
within the cancerous tissues or serum of such patients. Further-
more, a number of preliminary analyses suggest that certain
kallikreins including KLK3 (Yu et al, 1995; Yu et al, 1998; Foekens
et al, 1999), KLK5 (Yousef et al, 2002b, 2003c; Diamandis et al,
2003), KLK7 (Talieri et al, 2004), KLK9 (Yousef et al, 2003a),
KLK10 (Luo et al, 2002), KLK13 (Chang et al, 2002), KLK14
(Borgono et al, 2003), KLK15 (Yousef et al, 2002c) may possess
clinical utility as diagnostic, prognostic or predictive breast cancer
biomarkers. For recent reviews on the human kallikrein family
please see references (Diamandis and Yousef, 2002; Borgono and
Diamandis, 2004; Borgono et al, 2004; Clements et al, 2004).
Human kallikrein gene 14 (formerly known as KLK-L6) was
cloned in 2001 via the positional candidate approach (Hooper et al,
2001; Yousef et al, 2001). The KLK14 gene is under steroid
hormone regulation and is predominantly expressed in endocrine
tissues (breast, prostate, ovary, testes) as detected on the mRNA
and protein level (Yousef et al, 2001; Borgono et al, 2003; Yousef
et al, 2003b, 2003d). A recent study by Borgono et al (2003)
revealed that KLK14 protein levels are elevated in the serum of a
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sproportion of patients with breast cancer, implicating KLK14 as a
potential marker for breast cancer. However, conflicting data have
been obtained regarding the question whether KLK14 is over-
expressed in breast tumours compared to normal breast tissue.
Although one study reported loss of KLK14 expression in 21 of 25
analysed breast tumours in comparison to normal breast tissue
(Yousef et al, 2001), another study demonstrated abundant KLK14
expression in tumours and an association of high KLK14
expression with advanced disease (Yousef et al, 2002a). Thus, the
presently available data leaves the question open whether KLK14 is
a suitable biomarker for human breast cancer. Therefore, the main
focus of the present study was to carefully and quantitatively
analyse KLK14 protein expression in a large collection of human
breast normal and tumour specimens to further evaluate the
potential value of KLK14 for breast cancer prognosis.
MATERIALS AND METHODS
Patients
For immunohistochemistry, our study included 127 patients
diagnosed with primary breast cancer at the Institute of Pathology,
Charite ´ Universita ¨tsmedizin, Berlin, between 1991 and 1997.
Patient age at the time of diagnosis ranged from 30 to 87 with a
median of 57 years (mean 59). Follow-up data including overall
survival and disease recurrence or progression times were
available for all cases. The average observation time for overall
survival was 55 months for patients still alive at the time of
analysis, and ranged from 1 to 130 months. Twenty-two patients
(17%) died during follow-up and 43 patients (34%) experienced
disease progression defined by either metastatic or local recurrent
disease.
Adjuvant therapy was administered as follows: The first group
received either no or local therapy/radiotherapy (29 cases), or
systemic therapy excluding tamoxifen (20 cases). The second
group had received tamoxifen with or without an additional
systemic or local therapy (70 cases). For eight patients, no data on
adjuvant therapy was available.
The selection of cases for this study was based on availability of
tissue. Cases were not stratified for any known preoperative or
pathological prognostic factors. Cases with systemic disease (M1)
at the time of diagnosis were excluded. Tumour histology was
determined according to the criteria of the World Health
Organization (Tavassoli and Devilee, 2003), whereas disease stage
was assessed according to UICC (Wittekind et al, 2002). Tumours
were graded according to Bloom and Richardson, as modified by
Elston and Ellis (1993). Data regarding oestrogen receptor status
and the expression of c-erbB2 were taken from archival pathology
reports. Oestrogen receptor positivity was defined as an immuno-
reactive score (IRS) 43. Overexpression of c-erbB2 was defined
according to the clinical trial assay (2þ,3þ) as recommended in
the Hercep-test (DAKO). The clinicopathological characteristics of
the patients/tumours are described in Table 1.
RNA extraction from formalin-fixed paraffin-embedded
breast normal and tumour tissue
Archival formalin-fixed paraffin-embedded tissue from 25 breast
cancer specimens and 14 normal breast tissue specimens were
obtained from patients diagnosed at the Institute of Pathology of
the University Hospital of Aachen, Germany. For each formalin-
fixed paraffin-embedded tissue specimen six 4-mm thick tissue
sections were cut with a microtome (Leica, Germany) and
transferred to a water bath filled with DEPC-treated water.
Sections were mounted on standard glass slides and dried for 1h
at 601C. Sections were deparaffinised and rehydrated as follows:
2 15min in xylene, 2 15min in 100% ethanol, and short rinses
in 96, 70 and 50% ethanol followed by emersion in distilled water.
All tumour sections were manually microdissected to ensure a
minimum of 80% tumour cells. Tissue material was transferred to
a microcentrifuge tube and RNA was extracted according to the
Trizol protocol supplied by the manufacturer (Life Technologies,
Mannheim, Germany).
Quantitative RT-PCR
KLK14 mRNA-expression was analysed with the LightCycler
s
system (Roche Diagnostics, Germany) in archival formalin-fixed
paraffin-embedded breast cancer and normal breast tissue speci-
mens. b-Actin mRNA was used as reference. Primers used in this
study are presented in Table 2. Real-time RT-PCR was carried out
with Fast Start DNA master hybridisation probes (Roche
Molecular Biochemicals, Germany). The conditions were as
follows: initial denaturation in one cycle of 15min at 951C,
followed by 40 cycles at 951C for 20s, 601C( b-Actin) or 621C
(KLK14) for 20s and 721C for 30s. Reaction, data acquisition and
analysis were all performed by using the LightCycler
s instrument.
Gene expression was quantified by the comparative CT method,
Table 1 Clinicopathological parameters of the breast cancer patients
Variable Characteristic Number of cases %
Total number 127 100
Histology Invasive ductal 114 89.8
Invasive lobular 13 10.2
pT status pT1 84 66.1
pT2 33 26.0
pT3 4 3.1
pT4 6 4.7
Nodal status pN0 61 48.0
pN1 30 23.6
pN2 14 11.0
pN3 19 15.0
pNx 3 2.4
Grade G1 29 22.8
G2 64 50.4
G3 34 26.8
Age o60 72 56.7
4¼60 55 43.3
Adjuvant None/radiotherapy 29 22.8
Therapy Chemotherapy
only
20 15.7
Tamoxifen/
7chemotherapy
70 55.1
Oestrogen Negative 35 27.6
Receptor Positive 80 63.0
c-erbB2 0, 1+ 77 60.6
2+, 3+ 29 22.8
Table 2 Primers and probes used in real-time RT-PCR
Gene Primer sequence Product size
KLK14 50-AGTGTCAGGCTGGGGAACTA-30 183bp
50-CCCAGAGTCACCCTGACAAG-30
b-Actin 5-GGACGACATGGAGAAAATC-30 185bp
5-ATAGCACAGCCTGGATAGC-30
Human Kallikrein 14 expression in breast cancer
F Fritzsche et al
541
British Journal of Cancer (2006) 94(4), 540–547 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
snormalizing CT-values to the housekeeping gene b-Actin and
calculating the relative expression values of tumour and normal
tissues (Fink et al, 1998).
Anti-KLK14 antibody generation and cross-reactivity
analysis
Purified recombinant human Kallikrein 14 (100mg), produced as
the mature enzyme form in the Pichia pastoris expression system
as previously described (Felber et al, 2005), was used as an
immunogen and injected s.c. into New Zealand White female
rabbits for polyclonal antibody development. The protein was
diluted 1:1 in complete Freund’s adjuvant for the first injection and
in incomplete Freund’s adjuvant for subsequent injections.
Injections were repeated six times at 3-week intervals. Blood was
drawn from the animals and tested for antibody generation every 2
weeks.
Since KLK family proteins share 30–50% sequence similarity
(Yousef and Diamandis, 2001), the potential crossreactivity of the
a-KLK14 polyclonal rabbit antibody to other KLKs was evaluated
by Western blotting followed by densitometry of resultant bands.
Briefly, natural (KLK3) or recombinant (KLK1, 2, 4–15) hK
proteins produced in-house (100ng of KLK14; 1mg of other KLKs)
were separated on 4–12% gradient polyacrylamide gels at 200V
for 30min on the NuPAGE Bis-Tris electrophoresis system
(Invitrogen, Carlsbad, CA, USA). Proteins were then transferred
onto a Hybond-C extra nitrocellulose membrane (Amersham
Biosciences, Piscataway, NJ, USA) at 30V for 1h. The membrane
was blocked in Tris-buffered saline-Tween (0.1moll
 1 Tris-HCl
buffer (pH 7.5) containing 0.15moll
 1 NaCl and 0.1% Tween 20)
supplemented with 5% nonfat dry milk overnight at 41C. The
membrane was subsequently probed with the a-KLK14 polyclonal
rabbit antibody (diluted 1:2000 in Tris-buffered saline-Tween with
5% nonfat dry milk) for 1h at room temperature. After washing
the membrane three times for 15min and three times for 5min
with Tris-buffered saline-Tween, it was treated with an alkaline
phosphatase (ALP) conjugated goat anti-rabbit IgG antibody
(1:20000 in Tris-buffered saline-Tween with 5% milk; Jackson
Immunoresearch Inc., Pennsylvania, PA, USA) for 1h at room
temperature. The membrane was washed again as above and ALP
activity was detected on X-ray film using a chemiluminescent
substrate (Diagnostic Products Corporation, Los Angeles, CA,
USA). Developed films were scanned and resultant band intensities
were analysed by semiquantitative densitometry with Labworkst
4.0 Image Acquisition and Analysis Software (Ultra-Violet
Products Ltd., Upland, CA, USA). The a-KLK14 polyclonal rabbit
antibody exhibited less than 1% crossreactivity at a 1:1 weight ratio
between KLK14 and other KLKs (Figure 1).
Immunohistochemistry
Formalin-fixed paraffin embedded tissue was freshly cut (4mm).
The sections were mounted on superfrost slides (Menzel Gla ¨ser,
Braunschweig, Germany), dewaxed with xylene and gradually
hydrated. Antigen retrieval was achieved by pressure cooking in
0.01 M citrate buffer for 5min. The KLK14 antibody was diluted
1:1000 using a background reducing dilution buffer (DAKO,
Hamburg, Germany). No other blocking agents were employed.
The primary antibody was incubated at room temperature for 1h.
As a negative control, four slides were processed without primary
antibody. Detection was achieved by the conventional labelled-
streptavidin-biotin (DAKO, Hamburg, Germany) method with ALP
as the reporting enzyme according to the manufacturer’s instruc-
tions. Fast-Red (Sigma-Aldrich, Munich, Germany) served as
chromogen. Slides were briefly counterstained with haematoxylin
and mounted.
Evaluation of the immunohistochemical stainings
The immunostainings were independently examined by three
pathologists, who were blinded to patient outcome. The scoring
system for KLK14 staining was relatively simple so as to minimize
interobserver variability and enhance reproducibility in future
studies. Invasive carcinoma, intraductal carcinoma and adjacent
normal breast tissue were evaluated on each slide. We evaluated
the cytoplasmic staining intensity of KLK14 together with the
percentage of cells stained. An IRS was applied, as described by
Remmele and Stegner (1987) . The IRS is the product of staining
intensity (graded between negative¼0 and strong¼3) and the
percentage of positively stained cells (graded between 0 and 4,
being 1¼o25%, 2¼25–50%; 3¼51–75%, and 4¼475%,
respectively). Cases with discrepancies in IRS score among
pathologists were discussed until consensus was reached.
Statistical analysis
The data were analysed with the software package SPSS, version
12.0 (SPSS Inc., Chicago, USA). In order to compare the delta CT
values of the real-time RT-PCR results between specific groups the
nonparametric Mann–Whitney U-test was used. Fisher’s exact and
w
2 tests for trends were used to assess the statistical significance of
associations between KLK14 expression and clinico-pathological
parameters. Bivariate correlations according to Spearman were
applied to the IRS of normal tissue, intraductal and invasive
carcinomas. Univariate survival analysis was performed according
to Kaplan–Meier and differences in survival curves were assessed
with the Log rank test. P-values o0.05 were considered significant.
kDa
38 -
28 -
14 -
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Figure 1 Specificity of the a-KLK14 rabbit polyclonal antibody. Purified natural or recombinant KLKs 1–13 and 15 (1mg; lanes 1 through 14, respectively)
and recombinant KLK14 (100ng; lane 15) were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with a-KLK14 rabbit
polyclonal antibody (1:2000). At this 1:10 weight ratio between KLK14 and other KLKs, this a-KLK14 rabbit polyclonal antibody can weakly detect KLKs 7, 12,
13 and 15 (lanes 7, 12, 13 and 14, respectively), as demonstrated by the relatively low intensity bands. This corresponded to o1% crossreactivity at a 1:1
weight ratio between KLK14 and other KLKs, as determined by semiquantitative densitometry. M, molecular weight marker.
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Human kallikrein 14 (KLK14) mRNA expression
KLK14 mRNA expression was analysed by LightCycler
s RT-PCR
in a set of archival formalin-fixed paraffin-embedded tissue
specimens, consisting of 25 primary breast cancer (14 from
node-positive tumours, 11 from node-negative tumours) and 14
normal breast tissue samples. These data are presented in Figure 2.
In 40% (10 out of 25) of the breast tumours analysed, we detected
an at least two-fold upregulation in KLK14 mRNA expression
compared to the mean KLK14 expression in normal breast tissue.
Altogether, mean KLK14 mRNA expression in breast tumours
was 2.3-fold more abundant compared to the mean expression
of KLK14 mRNA in normal breast tissues; this difference was
statistically significant (P¼0.027, two-tailed Mann–Whitney
U-test). In this data set no significant association was found between
KLK14 expression level and histological grading, nodal status,
tumour size or HER2, oestrogen and progesterone receptor status.
Human kallikrein 14 immunostaining of breast tissue
KLK14 was expressed in a weak to intermediate fashion in 91% of
adjacent normal breast tissue (Figure 3A, Table 3). Intraductal
carcinomas adjacent to the invasive tumour were present in 77 of
the 127 cases. We observed cytoplasmic KLK14 expression in 99%
of intraductal carcinomas (Figure 3B, Table 3) and in 96% of
0.0
5.0
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15.0
20.0
25.0
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Figure 2 Diagrammatic presentation of quantitative RT-PCR data for KLK14 mRNA from formalin-fixed paraffin-embedded breast cancer (samples
1–25) and normal breast tissue specimens (samples A–N). Mean KLK14 expression was 3.0-fold upregulated in breast tumours as compared to the mean
expression in normal breast tissues (set equal to 1).
Figure 3 KLK14 immunohistochemistry in breast tissues. (A) Weak cytoplasmic immunoreactivity in secretory epithelia of normal lobular breast tissue.
(B) Strong immunostaining of ductal carcinoma in situ.( C and D) Strong immunostaining in invasive ductal carcinomas with a diffuse cytoplasmic (C) and
slightly granular pattern (D).
Human Kallikrein 14 expression in breast cancer
F Fritzsche et al
543
British Journal of Cancer (2006) 94(4), 540–547 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sinvasive carcinomas, respectively (Figure 3C and D, Table 3),
which was significantly stronger than in normal tissue (P¼0.003,
Fisher’s exact test). The IRS score in adjacent normal tissue
(median IRS¼2), intraductal (median IRS¼4) and invasive
carcinomas (median IRS¼4) was significantly correlated (all
Po0.001, Table 3). This implies that cases with higher IRS scores
in normal adjacent tissues were likely to have higher IRS scores in
the tumour. To correct for interindividual staining qualities, we
normalized the KLK14 immunoreactivity in carcinomas by
subtracting the IRS of the normal tissue from the corresponding
tumour IRS. Cases in which the tumour stained stronger than
adjacent normal tissue (IRS4¼1) were considered as tumours
with high KLK14 expression. KLK14 was shown to be over-
expressed in 61% (78 out of 127 cases) of invasive breast
carcinomas compared to the adjacent normal breast tissues. In
18% (23 out of 127 cases) and 21% (26 out of 127 cases) KLK14
expression was equal and higher in adjacent normal tissue
compared to invasive carcinoma, respectively. There was a
significant association of high KLK14 expression with higher
tumour grade (P¼0.041) and positive nodal status (P¼0.045).
KLK14 expression was not significantly associated with any other
clinico-pathological parameters as shown in Table 4.
Kallikrein 14 expression and survival
Histological grade, tumour size and nodal status were significant
predictors of both overall and disease-free survival (Tables 5–7).
However, KLK14 expression was not associated with either
disease-free or overall patient survival. Kaplan–Meier survival
curves (Figure 4A and B) indicate that patients with KLK14-
negative tumours tended to exhibit a slightly increased overall
survival compared to patients with KLK14-positive tumours;
however, these results did not reach statistical significance. As
previous results related KLK14 to steroid response, we performed
survival analyses for KLK14 expression stratified for oestrogen
receptor status and endocrine therapy but did not find any
significant results for neither disease-free or overall survival (data
not shown).
DISCUSSION
In the present study, we carefully analysed KLK14 expression in
normal and malignant breast tissue both on the RNA and protein
level to further evaluate the potential value of KLK14 as a
diagnostic marker in breast cancer. Using real-time RT-PCR we
could clearly demonstrated KLK14 mRNA overexpression in breast
cancer compared to normal breast tissue. These data are in conflict
to a recent RT-PCR study, which showed loss of KLK14 expression
in 21 of 25 (84%) human breast cancer analysed (Yousef
et al, 2001). However, our data are in agreement with another
quantitative RT-PCR study that described much more abundant
KLK14 expression (in 55 of 178 breast tumours) and a clear
correlation of KLK14 expression and poor prognosis (Yousef et al,
2002a). The possible explanation for these disparities could be that
our study and that of Yousef et al (2002a) used the more accurate
quantitative RT-PCR technique.
The present study is the first to analyse KLK14 protein
expression in a large cohort of human breast cancer specimens
in comparison to matching normal breast tissues using a recently
characterised KLK14-specific antibody (Felber et al, 2005). This
KLK14 antibody demonstrated KLK14 protein overexpression
in 61% of analysed tumour/normal tissue pairs. Next, we analysed
the KLK14 protein expression data in relation to established
prognostic indicators and patient survival and we found a
significant correlation of KLK14 protein expression with tumor
grade and nodal status. Currently oestrogen receptor- and cerbB2-
status represent the most important immunohistochemical
diagnostic markers in breast cancer. Widely used, they provide
clinically important information about the tumour biology and
offer additional treatment options. This lead to a more individua-
Table 3 KLK14 staining, immunoreactive score (IRS) and bivariate correlations in normal breast tissue, intraductal and invasive carcinoma
Type of tissue
Percentage of
tissue stained (n) IRS median IRS mean
Correlation with
invasive carcinoma
Normal breast (n¼127) 91 (115) 2 2.9 CC¼0.361
Po0.001
Intraductal carcinoma (n¼77) 99 (76) 4 5.1 CC¼0.757
Po0.001
Invasive carcinoma (n¼127) 96 (125) 4 4.2
CC¼Correlation coefficient and P¼P value.
Table 4 Associations between KLK14 expression and clinical-patholo-
gical parameters
No. of patients (%)
Variable Patients KLK14 low KLK14 high P-value
Patient age 0.582
o60 years 72 46 (63.9) 26 (36.1)
4¼60 years 55 32 (58.2) 23 (41.8)
Histology 0.246
Ductal 114 72 (63.2) 42 (36.8)
Lobular 13 6 (46.2) 7 (53.8)
pT status 0.323
a
pT1 84 48 (57.1) 36 (42.9)
pT2 33 24 (72.7) 9 (27.3)
pT3/4 10 6 (60.0) 4 (40.0)
PN status 0.045
pN0 61 29 (47.5) 32 (52.5)
pN1+ 64 19 (29.7) 45 (70.3)
Histological grade 0.041
G1/2 93 41 (44.1) 52 (55.9)
G3 34 8 (23.5) 26 (76.5)
Oestrogen receptor 0.211
Negative 35 10 (28.6) 25 (71.4)
Positive 80 34 (42.5) 46 (57.5)
CerbB2 expression 1
0, 1+ 77 31 (40.3) 46 (59.7)
2+, 3+ 29 11 (37.9) 18 (62.1)
Therapy 0.563
None/local/CTx 49 20 (40.8) 29 (59.2)
Tamoxifen7CTx 70 24 (34.3) 46 (65.7)
aw
2 test for trends.
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slized cancer therapy with antihormonal drugs or trastuzumab
antibody (Fuqua and Cui, 2002; Bell et al, 2004), both of which
improved patient outcome in selected patient cohorts. It remains
to be focus of further study, whether KLK14 offers independent
additional information in breast cancer or if KLK14 could be a
potential target of specific therapy.
An earlier study by Yousef et al (2002a) examined the
prognostic value of KLK14 expression in 178 breast cancer on
the RNA level and found that high KLK14 mRNA expression was
associated with advanced stage (III) disease. KLK14 also was
an independent predictor of decreased disease-free and overall
survival. The cutoff value in this study (Yousef et al, 2002a) for
KLK14 positive and negative tumours was defined by its ability
to predict disease-free and overall survival and resulted in the
definition of KLK14 positivity in 31% of breast tumours. In our
study, we decided to use the median of KLK14 expression to
delineate groups of low and high expression levels. With this cutoff
value a significant association between KLK14 and tumour grading
and positive nodal status was shown, both of which are indicators of
a more aggressive course of disease. Alterations in the cutoff values
to adapt the KLK14 postitive/negative ratio to the aforementioned
study did not lead to any significant results (data not shown).
Table 5 Disease-free and overall survival according to clinicopathological variables and kallikrein 14 expression (univariate analysis)
Disease-free survival Overall survival
Characteristic
No. of
cases
No. of
events
5-year survival rate
(7s.e.) P-value
No. of
cases
No. of
events
5-year
nonprogression
rate (7s.e.) P-value
KLK14 expression 0.306 0.602
Low 49 18 64.576.9 49 7 89.074.4
High 78 25 64.777.6 78 15 83.175.5
Age 0.163 0.623
o60 years 72 28 55.977.1 72 14 88.674.1
4¼60 years 55 15 77.376.1 55 8 86.875.1
Histology 0.929 0.856
Ductal 114 39 61.2715.8 114 20 86.073.7
Lobular 13 4 65.175.3 13 2 90.978.7
pT status 0.001 0.001
pT1 84 21 76.975.4 84 6 94.672.6
pT2 33 18 33.4711.1 33 11 75.279.0
PT3/4 10 4 60.0715.5 10 5 60.0719.3
Nodal status 0.0295 0.001
PN0 61 13 78.576.3 61 2 96.272.6
PN1+ 64 28 55.177.3 64 20 77.775.7
Histological grade 0.0155 0.043
G1/2 93 12 72.975.5 93 12 89.973.7
G3 34 10 41.4710.4 34 10 77.577.5
Oestrogen receptor 0.7379 0.379
Negative 35 12 67.278.8 35 9 84.876.3
Positive 80 27 64.576.6 80 12 85.274.6
c-erbB2 expression 0.394 0.301
0, 1+ 77 24 71.876.4 77 12 87.074.3
2+, 3+ 29 11 56.4710.1 29 6 84.377.2
Table 6 Cox univariate and multivariate analysis for disease-free survival.
Variables were grouped according to Tables 4 and 5
Variable
Relative
risk
Confidence
interval (95%) P-value
Univariate analysis
Kallikrein 14 1.370 0.746–2.517 0.310
pT status 1.441 1.044–1.990 0.026
Nodal status 2.479 1.450–4.237 0.001
Histological grade 2.539 1.543–4.178 o0.001
Multivariate analysis
Kallikrein 14 0.572 0.292–1.119 0.103
pT status 0.845 0.495–1.442 0.536
Nodal status 2.078 0.942–4.584 0.070
Histological grade 2.159 1.033–4.514 0.041
Table 7 Cox univariate and multivariate analysis for overall-free survival.
Variables were grouped according to Tables 4 and 5
Variable
Relative
risk
Confidence
interval (95%) P-value
Univariate analysis
Kallikrein 14 1.269 0.516–3.120 0.604
pT status 2.150 1.394–3.316 0.001
Nodal status 4.313 1.654–11.250 0.003
Histological grade 2.521 1.265–5.022 0.009
Multivariate analysis
Kallikrein 14 1.107 0.407–3.013 0.843
pT status 1.611 0.820–3164 0.166
Nodal status 4.434 0.889–22.106 0.069
Histological grade 1.391 0.512–3.777 0.517
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represent a new biomarker for breast cancer, having shown KLK14
serum levels to be elevated in eight out of 20 (40%) breast cancer
patients. This equals the KLK14 elevation in breast cancer tissues
we observed in 40 and 61% of cases on RNA and protein level,
respectively, and thus may account for the KLK14 elevation in the
serum of a proportion of breast cancer patients.
Although the potential pathobiological role of KLK14 in breast
cancer has not been elucidated, several lines of evidence suggest
that KLK14, like many other kallikreins, may be causally involved
in breast tumour progression (Borgono and Diamandis, 2004;
Felber et al, 2005). This is substantiated by the fact that KLK14, via
its serine protease activity, is able to degrade components of the
extracellular matrix, including collagen IV a1 chain, collagen XII
and matrilin-4 in vitro, which may promote tumour cell invasion
and metastasis in vivo (Felber et al, 2005). These findings may have
therapeutic applications by targeting KLK14 in appropriate
patients.
In conclusion, although our data provides further evidence to
support the association of KLK14 with aggressive breast cancer,
immunohistochemically determined KLK14 expression in primary
breast cancer does not appear to have additional prognostic value
for the surgical pathologist. Further basic and clinical studies are
warranted to clarify the potential role of KLK14 in the progression
of breast cancer.
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Figure 4 Univariate survival curves (Kaplan–Meier) for overall (A) and disease-free (B) survival according to high (bold line) versus low (dotted line)
KLK14 expression. The number patients in the high and the low expression group were 78 and 49, respectively. The number of events in each group is
stated in brackets.
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